Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies
Bioprocess International Conference in Boston panel.
New dimensions in 3D bioprinting
Late stage failures in drug development are extremely costly for pharmaceutical companies and stifle innovation. Now non-traditional methods such as 3D bioprinting are being brought to bear on this challenge.
Navigating the market for “PoC” diagnostic systems
Several companies have developed, or are currently developing, products for the “point-of-care” molecular diagnostics market. In reality, the molecular diagnostics market is heterogeneous, and few applications are likely to arise truly at the point of care—indeed “point-of-clinic” would be a better description for this market.
Predicting failure rates in cell therapy manufacturing: is one in a million good enough?
Autologous cell therapy has had some remarkable clinical success, but to get to where it is today, industry has relied heavily on repurposed R&D equipment to manufacture individual batches of cell therapy.
Editing the genomes of superbugs to combat antibiotic resistance
Pathogenic bacteria that resist nearly all antibiotics are continuing to spread worldwide, the human population is getting sicker, and experts are scrambling to fix the problem. Innovative approaches that target bacterial genomes may be part of a much-needed solution to the growing crisis of antibiotic resistance.
The Future of Human Healthcare: Rise of the Netborgs
TTP welcomes guest author Frank F Craig PhD MBA of Sphere Fluidics Limited to the blog.
How many cells should a therapeutic cell sorter sort?
Genetic engineering of CAR T-cells for therapeutic applications is going through an explosion of sophistication, which places great demands on gene transfection, transduction and cell separation technologies.
MEMS evolution: from Silicon to Polymers
In the beginning…
CRISPR-Cas9 – A chink in the armour of the white knight?
Anyone even remotely linked to the field of Molecular Biology will have noticed the escalation in use of the CRISPR-Cas9 gene editing tool over the past five years. First used for genome editing by teams at both Harvard and MIT and published in 2013, CRISPR is now featured in thousands of publications every year, a number that is increasing rapidly.
Nanopore sensors – Not just for sequencing
In a world dominated by computers it is still a challenge for electronics to interact with the molecules that control our bodies, cause disease and make up important industrial chemicals.